Search This Blog

Monday, March 2, 2026

Aardvark Therapeutics pauses Phase 3

 

Aardvark Therapeutics pauses Phase 3 HERO trial of ARD-101 in Prader-Willi after cardiac findings as RBC, Stifel, Morgan Stanley, HC Wainwright cut ratings

  • Pause followed reversible cardiac observations in an ARD-101 healthy volunteer study, which the company described as reversible.
  • Pause delays HERO trial's topline data timeline for ARD-101 in Prader-Willi syndrome.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)